Oncology

TIP60 levels could serve as a prognostic marker of breast cancer progression.

An investigational drug was found to reverse the activity of immune suppressor cells.

Top news of the day from across the health care landscape.

A modified retrovirus may hold the key to successful gene therapy for patients with a serious immune system disorder.

The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) found to be active and safe in relapsed/refractory classical Hodgkin lymphoma.

Roche’s bevacizumab (Avastin) granted expanded indication for platinum-sensitive recurrent ovarian cancer.

Avastin was previously approved for the treatment of metastatic colorectal cancer, lung cancer, brain cancer, kidney cancer, and cervical cancer.

New skin cancer combination therapy more effective than current treatments.

Oraxol is combination P-glycoprotein pump inhibitor and an oral version of paclitaxel.

Majority of people with chronic hepatitis C are unaware of the infection.

Mouth cancer rates show significant increase among males and females of all ages.

Partnership between Clearbrdige BioMedics and John Wayne Cancer Institute will initially focus on melanoma.

Trained clinical pharmacists can effectively manage patients with hepatitis C virus.

Have you ever considered pursuing a post-graduate year 2 pharmacy residency in oncology?

Trisenox is the first approved acute leukemia treatment that is chemotherapy-free.

Top news of the week in oncology and cancer drug development.

Reovirus may treat primary liver cancer and hepatitis C virus.

The new method makes breast imaging less risky, and can lessen false-positive readings.

New treatments show promise harnessing the immune system to attack late-stage skin cancer.

Trametinib targets a type of immune cell that inhibits T cell response in cancer.

Top news of the day from across the health care landscape.

A novel drug used in combination with radiation found to be a more effective treatment for prostate cancer.

About 1 in 6 women diagnosed with breast cancer have a symptom other than a lump.

New findings show that treatment with cabozantinib decreased mortality risk by 20% in patients with metastatic kidney cancer.

Increased levels of tumor-associated myeloid cells reduce cancer cell sensitivity to treatments.

Women who display non-lump breast cancer symptoms are less likely to seek needed care.

Determining the contents of extracellular vesicles may create targeted treatments.

Different hepatitis C genotypes are more prominent in certain areas than others.